|
Name |
Chaetomugilin Q
|
Molecular Formula | C22H29ClO6 | |
IUPAC Name* |
(7S,8S)-5-chloro-7-hydroxy-8-[(3S,4S)-4-hydroxy-3-methyl-2-oxopentyl]-3-[(E,3R,4R)-4-hydroxy-3-methylpent-1-enyl]-7-methyl-8H-isochromen-6-one
|
|
SMILES |
C[C@H](/C=C/C1=CC2=C(C(=O)[C@@]([C@H](C2=CO1)CC(=O)[C@@H](C)[C@H](C)O)(C)O)Cl)[C@@H](C)O
|
|
InChI |
InChI=1S/C22H29ClO6/c1-11(13(3)24)6-7-15-8-16-17(10-29-15)18(9-19(26)12(2)14(4)25)22(5,28)21(27)20(16)23/h6-8,10-14,18,24-25,28H,9H2,1-5H3/b7-6+/t11-,12+,13-,14+,18+,22+/m1/s1
|
|
InChIKey |
VWKWLVNURGSWPO-WGGDPNRLSA-N
|
|
Synonyms |
Chaetomugilin Q; CHEMBL1797230
|
|
CAS | NA | |
PubChem CID | 53358199 | |
ChEMBL ID | CHEMBL1797230 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 424.9 | ALogp: | 1.4 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 29 | QED Weighted: | 0.577 |
Caco-2 Permeability: | -4.599 | MDCK Permeability: | 0.00001850 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.64 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.034 |
Blood-Brain-Barrier Penetration (BBB): | 0.781 | Plasma Protein Binding (PPB): | 74.56% |
Volume Distribution (VD): | 1.073 | Fu: | 15.46% |
CYP1A2-inhibitor: | 0.707 | CYP1A2-substrate: | 0.282 |
CYP2C19-inhibitor: | 0.156 | CYP2C19-substrate: | 0.76 |
CYP2C9-inhibitor: | 0.083 | CYP2C9-substrate: | 0.076 |
CYP2D6-inhibitor: | 0.195 | CYP2D6-substrate: | 0.033 |
CYP3A4-inhibitor: | 0.814 | CYP3A4-substrate: | 0.654 |
Clearance (CL): | 3.696 | Half-life (T1/2): | 0.422 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.861 |
Drug-inuced Liver Injury (DILI): | 0.737 | AMES Toxicity: | 0.014 |
Rat Oral Acute Toxicity: | 0.947 | Maximum Recommended Daily Dose: | 0.361 |
Skin Sensitization: | 0.678 | Carcinogencity: | 0.948 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.027 |
Respiratory Toxicity: | 0.98 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005878 | 0.807 | D03KIA | 0.250 | ||||
ENC005844 | 0.807 | D0JE2E | 0.224 | ||||
ENC002778 | 0.724 | D08GHB | 0.205 | ||||
ENC002610 | 0.724 | D02GAC | 0.191 | ||||
ENC004405 | 0.576 | D0R6RC | 0.191 | ||||
ENC002612 | 0.574 | D0Z1WA | 0.188 | ||||
ENC005437 | 0.560 | D0L5FY | 0.186 | ||||
ENC002178 | 0.542 | D0C8HR | 0.183 | ||||
ENC002611 | 0.515 | D0U9QU | 0.183 | ||||
ENC002501 | 0.500 | D06YFA | 0.182 |